Cargando…

Long-term treatment of patients with HIV-1: the role of atazanavir

BACKGROUND: The introduction of highly-active antiretroviral therapy (HAART) remains a major milestone in the management of HIV-infected patients. Protease inhibitors (PI) are commonly used as part of triple combinations, given that to antiviral potency, better tolerance and convenience has been ach...

Descripción completa

Detalles Bibliográficos
Autores principales:	Artacho, Miguel Ángel, Barreiro, Pablo, Fernández-Montero, José Vicente
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2010
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3218682/ https://www.ncbi.nlm.nih.gov/pubmed/22096394 http://dx.doi.org/10.2147/HIV.S5069

Ejemplares similares

Role of atazanavir in the treatment of HIV infection
por: Rivas, Pablo, et al.
Publicado: (2009)

Coronavirus and other airborne agents with pandemic potential
por: Fernandez-Montero, Jose Vicente, et al.
Publicado: (2020)

Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection
por: Crutchley, Rustin D, et al.
Publicado: (2016)

External Validation of the Bilirubin–Atazanavir Nomogram for Assessment of Atazanavir Plasma Exposure in HIV-1-Infected Patients
por: Rekić, Dinko, et al.
Publicado: (2012)

Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced HIV patients
por: Jansen, K, et al.
Publicado: (2010)

Long-Term Gender-Based Outcomes for Atazanavir/Ritonavir (ATV/r)-Containing Regimens in Treatment-Experienced Patients with HIV
por: Svedhem-Johansson, Veronica, et al.
Publicado: (2013)

AIDS Clinical Research in Spain—Large HIV Population, Geniality of Doctors, and Missing Opportunities
por: Soriano, Vicente, et al.
Publicado: (2018)

Atazanavir nephrotoxicity
por: Hara, Masaki, et al.
Publicado: (2015)

Metabolic and Kidney Disorders Correlate with High Atazanavir Concentrations in HIV-Infected Patients: Is It Time to Revise Atazanavir Dosages?
por: Gervasoni, Cristina, et al.
Publicado: (2015)

Antenatal Atazanavir: A Retrospective Analysis of Pregnancies Exposed to Atazanavir
por: Samuel, Miriam, et al.
Publicado: (2014)

Hyperbilirubinemia in atazanavir treated HIV-infected patients: the impact of the UGT1A1*28 allele
por: Panagopoulos, Periklis, et al.
Publicado: (2017)

Analysis of determinants of long-term efficacy of unboosted atazanavir-based regimens in the clinical setting
por: Bonora, S, et al.
Publicado: (2010)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir
por: Beckman, Joshua A., et al.
Publicado: (2017)

Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients
por: Ferretti, Francesca, et al.
Publicado: (2016)

Cardiovascular outcomes among HIV-infected veterans receiving atazanavir
por: LaFleur, Joanne, et al.
Publicado: (2017)

Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study
por: Teófilo, Eugénio, et al.
Publicado: (2016)

No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients
por: Gutierrez-Valencia, Alicia, et al.
Publicado: (2018)

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
por: Robertson, Kevin, et al.
Publicado: (2018)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States
por: Brogan, Anita J., et al.
Publicado: (2018)

1572 Impact of Hyperbilirubinemia on Persistence and Adherence of Atazanavir among HIV Patients
por: Rosenblatt, Lisa, et al.
Publicado: (2014)

Lopinavir to atazanavir or darunavir switch in HIV-1-infected patients with dyslipidemia: an observational study
por: Le Moal, G, et al.
Publicado: (2010)

Long-term efficacy and safety of low-dose ritonavir-boosted atazanavir (ATV/r) 200/100 mg in HIV-infected Thai patients
por: Avihingsanon, A, et al.
Publicado: (2010)

Effectiveness and Safety of Atazanavir Use for the Treatment of Children and Adolescents Living With HIV: A Systematic Review
por: Saint-Lary, Laura, et al.
Publicado: (2022)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

Pharmacologic Boosting of Atazanavir in Maintenance HIV-1 Therapy: The COREYA Propensity-Score Adjusted Study
por: Hocqueloux, Laurent, et al.
Publicado: (2012)

Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers
por: Dickinson, Laura, et al.
Publicado: (2009)

Association Between Atazanavir‐Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV
por: Li, Michael, et al.
Publicado: (2020)

Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study
por: Llibre, Josep M., et al.
Publicado: (2016)

Therapeutic drug monitoring (TDM) of atazanavir in pregnancy
por: Else, LJ, et al.
Publicado: (2010)

Predictors of the change in bilirubin levels over twelve weeks of treatment with atazanavir
por: Cotter, Aoife G, et al.
Publicado: (2013)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

SLCO3A1 expression is a major determinant of atazanavir PBMC penetration in HIV-infected patients
por: Siccardi, M, et al.
Publicado: (2010)

Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients
por: Orrell, Catherine, et al.
Publicado: (2015)

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial
por: Restelli, Umberto, et al.
Publicado: (2017)

Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy
por: Dubrocq, Gueorgui, et al.
Publicado: (2017)

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers
por: Dumond, JB, et al.
Publicado: (2016)

Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
por: Giacomelli, Andrea, et al.
Publicado: (2014)

Repurposing HIV Protease Inhibitors Atazanavir and Darunavir as Antifungal Treatments against Candida albicans Infections: An In Vitro and In Vivo Study
por: Fenley, Juliana de C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_j74r73r1ih5vj79i31edeq310n